Primary octreotide LAR therapy in GH-secreting pituitary adenoma

Journal of the Indian Medical Association

Volumn 102, Issue 5, 2004, Pages 258-261

  Harinarayan, C V ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

GH secreting pituitary adenoma; Octreotide LAR; Primary therapy

Indexed keywords

GADOLINIUM; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AORTA STENOSIS; ARTICLE; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPOPHYSIS ADENOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNATHIA; SELLA TURCICA;

EID: 9644253138     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Davis DH, Laws ER Jr, Ilstrup DM, Speed JK, Caruso M, Shaw EG, et al - Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 1993; 79: 70-5.
2. Freda PU, Wardlaw SL, Post KD - Long-term endocrinological follow-up after transsphenoidal surgery and adjuvant therapy for acromegaly. J Neurosurg 1998; 89: 353-8.
3. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al - Long-term mortality after transsphenoidal surgery. J Clin Endocrinol Metab 1998; 83: 3419-26.
4. Laws ER Jr, Chenelle AG, Thapar K - Recurrence after transsphenoidal surgery for pituitary adenomas: clinical and basic science aspects. In: von Werder K, Fahlbusch R, editors. Pituitary Adenomas: From Basic Research to Diagnosis and Therapy. Amsterdam: Elsevier, 1996: 3-9.
5. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ - Octreotide. N Engl J Med 1996; 334: 246-54.
6. Grass P, Marbach P, Bruns C, Lancranjan I - Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45: 27-30.
7. Barkan AL, Lloyd RV, Chandler WF, Gebarski SS, Kelch RP, Beitins IZ - Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-8.
8. Lancranjan I, Atkinson AB and the Sandostatin LAR® Group - Results of a European Multicentre Study with Sandostatin® LAR® in acromegalic patients. Pituitary 1999; 1: 105-14.
9. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al - Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-40.
10. Melmed S, Jackson I, Kleinberg D, Klibanski A - Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998; 83: 2646-52.